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Abstract The solution structure of an apoA-I deletion mutant,
apoA-I(1^186) was determined by the chemical shift index (CSI)
method and the torsion angle likelihood obtained from shift and
sequence similarity (TALOS) method, using heteronuclear
multidimensional NMR spectra of [u-13C, u-15N, u-50%
2H]apoA-I(1^186) in the presence of sodium dodecyl sulfate
(SDS). The backbone resonances were assigned from a
combination of triple-resonance data (HNCO, HNCA,
HN(CO)CA, HN(CA)CO and HN(COCA)HA), and intraresi-
due and sequential NOEs (three-dimensional (3D) and four-
dimensional (4D) 13C- and 15N-edited NOESY). Analysis of the
NOEs, HK, CK and CP chemical shifts shows that apoA-I(1^186)
in lipid-mimetic solution is composed of K-helices (which include
the residues 8^32, 45^64, 67^77, 83^87, 90^97, 100^140, 146^
162, and 166^181), interrupted by short irregular segments.
There is one relatively long, irregular and mostly flexible region
(residues 33^44), that separates the N-terminal domain (residues
1^32) from the main body of protein. In addition, we report, for
the first time, the structure of the N-terminal domain of apoA-I
in a lipid-mimetic environment. Its structure (K-helix 8^32 and
flexible linker 33^44) would suggest that this domain is
structurally, and possibly functionally, separated from the other
part of the molecule. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Apolipoprotein A-I (apoA-I) is the principal protein com-
ponent of high density lipoproteins (HDL) and is responsible
for the formation of HDL particles. ApoA-I is the major
activator of the enzyme LCAT, which participates in a key
step in the reverse transport of cholesterol. Reverse cholester-
ol transport involves di¡usion of unesteri¢ed cholesterol from
peripheral tissue to lipoproteins, esteri¢cation of lipoprotein
cholesterol by LCAT and lipoprotein transport of esteri¢ed
cholesterol to the liver for catabolism and excretion into the
bile [1].
ApoA-I is hydrophobic, aggregates in aqueous solution,
and has two 11 and eight 22 residue tandem repeats, which
were proposed to form amphipathic helices with distinct hy-
drophilic and hydrophobic faces [2,3]. It is known from mu-
tant proteins [4,5] and mutagenesis studies [6^8] that certain
regions of apoA-I are responsible for lipid binding and acti-
vation of LCAT.
In the present communication we report the preparation by
bacterial expression, and a multidimensional heteronuclear
NMR study of [u-13C; u-15N; u-50% 2H]apoA-I(1^186). The
NMR spectra were determined in excess SDS. NMR studies
of lipid-associating proteins are often conducted in the pres-
ence of SDS which serves as a model for a membrane environ-
ment [9,10]. SDS micelles are V5 nm in diameter, which is
similar in size to the pre-L-HDL and to the smallest HDL3,
hence are likely to yield a conformation resembling the apoA-
I structure present in HDL. In fact, SDS was shown to model
the lipoprotein environment for apoA-I peptides [11^13].
From the heteronuclear NMR data we were able to assign
the backbone atom (1H, 13C and 15N) chemical shifts and to
establish the solution secondary structure of apoA-I(1^186) in
a lipid-mimetic environment. To our knowledge, this is the
largest exchangeable apolipoprotein, whose solution lipid-
bound structure has been resolved.
2. Materials and methods
2.1. Sample production and puri¢cation
The C-terminal deletion mutant, apoA-I(1^186), molecular weight
23 067, includes the N-terminal extension Met-Arg-Gly-Ser-(His)6-
Met [14]. It was expressed in a bacterial system described earlier
[15], using Martek 9-CN media containing 98% 13C and 15N with
50% 2H (Martek Biosciences, Columbia, MD, USA). After puri¢ca-
tion on nitriloacetic acid agarose (NTA, Qiagen), the uniformly la-
beled protein (7.5 mg/l media) was dialyzed against 5 mM NH4HCO3,
and lyophilized.
2.2. Circular dichroic measurements
Circular dichroic spectroscopy was performed using a Jasco J41A
spectropolarimeter, as previously described [8]. The percentage of
K-helix content was calculated from the molar ellipticity at 222 nm
and using a mean residue weight of 115.2 for native apoA-I and 115.5
for apoA-I(1^186).
2.3. NMR spectroscopy
A 1 mM solution of [u-13C; u-15N; u-50% 2H]apoA-I(1^186) in
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 2 3 7 5 - 9
*Corresponding author. Fax: (1)-604-291 5583.
E-mail: cushley@sfu.ca
Abbreviations: apo, apolipoprotein; HDL, high density lipopro-
tein(s); VLDL, very low density lipoprotein(s); LCAT, lecithin:cho-
lesterol acyltransferase; CD, circular dichroism; SDS, sodium dodecyl
sulfate; NOESY, nuclear Overhauser enhancement spectroscopy;
HSQC, heteronuclear single quantum coherence; CT, constant time;
CSI, chemical shift index; TALOS, torsion angle likelihood obtained
from shift and sequence similarity
FEBS 24466 4-1-01
FEBS 24466FEBS Letters 487 (2001) 390^396
95% H2O:5% D2O, 3 mM EDTA, pH 6.4, was prepared containing
SDS^d25. The protein:SDS ratio was 1:140 mol/mol. NMR spectra
were recorded at 39‡C on a Bruker AMX-600 spectrometer operating
at 600.13 MHz (1H) and equipped with a Z-gradient triple-resonance
probe.
A two-dimensional (2D) 1H/15N HSQC spectrum [16] was acquired
with 256U256 complex points and spectral widths of 5.667 (1H) and
31.145 (15N) ppm (64 transients).
The 3D 15N-edited, gradient-enhanced NOESY-HSQC [17] spec-
trum was recorded with a mixing time of 150 ms. Due to hardware
and software restrictions, only four pulse ¢eld gradients instead of 12,
and a smaller number of hard 15N pulses, were used. A series of
constant time (CT) triple-resonance pulse sequences, CT-HNCO,
CT-HNCA and CT-HN(CO)CA [18], were used with the following
modi¢cations: (i) pulse ¢eld gradients were used to minimize the
artifact content of the spectra [19] and (ii) a WATERGATE pulse
sequence was used to suppress the water signal [20]. A CT-HN(CA)-
CO experiment was used, which was a modi¢cation of the 3D CT-
HN(CO)CA mentioned above and where an HSQC instead of an
HMQC step in the CP-CK magnetization transfer was inserted. Fi-
nally, a 3D HN(COCA)HA experiment was used, based on a 4D
HN(CO)CAHA pulse sequence [21] without a CK evolution time.
WATERGATE and pulse ¢eld gradient sequences were added as
well. The CBCA(CO)NH experiment [22] was made without modi¢-
cations.
A 4D 15N/13C-edited NOESY [23] spectrum was recorded based on
the 3D 15N-edited gradient-enhanced NOESY-HSQC spectrum (see
above). A 4D 15N/13CP-edited NOESY-HNCO spectrum was recorded
using the 3D 13CP-edited NOESY-H(N)CO pulse sequence [24] to
which a 15N dimension was added.
In general, the acquisition dimension was collected with a spectral
width of 2.4 ppm, using 256 complex points with the carrier position
at 8.0 ppm (the center of the HN region). Spectral widths in the
indirectly detected 15N, 13CP and 13CK dimensions were 24.0, 12.1,
and 31.14 ppm, respectively, with the carrier positions at 116.5,
177.0, and 56.0 ppm, respectively. The number of acquired complex
points for 3D CT experiments were 30 for 15N and 48 for 13C and
mirror linear prediction was used to increase the resolution in the 15N
dimension. For the CT-HN(COCA)HA experiment the spectral width
for indirectly detected 1H was 2.0 ppm, using 28 complex points with
the carrier set at 4.33 ppm.
The 4D 15N/13C-edited NOESY was collected with spectral widths
of 2.4, 24.0, 7.6, and 23.9 ppm in directly detected HN and indirectly
detected 15N, 1H, and 13C dimensions, respectively. The numbers of
acquired complex points were 256, 16, 64, and 16, respectively. The
spectral widths and numbers of acquired complex points for 4D 15N/
13CP-edited NOESY-HNCO were 2.4, 9.0, 24.0, and 8.5 ppm and 128,
64, 14, and 6 points in HN, 1H, 15N, and 13CP dimensions, respec-
tively.
The numbers of transients were 8^96 for 3D and 1^2 for 4D experi-
ments. Proton chemical shifts were referenced to internal 2,2-dimeth-
yl-2-silapentane-5-sulfonic acid (DSS) directly, and 13C and 15N chem-
ical shifts were indirectly referenced to DSS [25].
Data were processed and analyzed on an SGI O2 workstation using
nmrPipe/nmrDraw [26] and NMRView3 [27]. NMRView3 was also
used for sequential assignments. The chemical shift data will be avail-
able from the BioMagResBank after 09/01/2001.
2.4. Structure analysis
The secondary structure was determined from the 1H, 13C and 15N
chemical shift values using CSI [25,28^30] and the TALOS program
[31]. Secondary chemical shifts used as input for CSI were calculated
by subtracting the measured chemical shifts of apoA-I(1^186) in SDS^
d25 complexes from the corresponding random coil values [32]. A
combination of four kinds (1HK, 13CK, 13CP and 15N) of chemical
shifts was used for TALOS [31] prediction of phi and psi backbone
torsion angles. TALOS uses shift data for three consecutive residues,
the ‘triplet’, and compares it with similar triplets in a database. The
10 best matches to a given triplet were tested for consistency of phi
and psi angles and their averages and standard deviations were used
for predicting apoA-I(1^186) structure. The TALOS database con-
tains 20 proteins with known high resolution crystal structures
(3032 triplets). Although Fig. 3 represents the exact values of pre-
dicted TALOS angles, TALOS structure predictions were analyzed
exclusively in a CSI-like manner in accordance with the following
relationships:
Then, CSI and TALOS predictions were analyzed in common using
CSI rules. The resulting apoA-I(1^186) structure (depicted in Figs. 3
and 4) is the result of consensus between CSI and TALOS.
2.5. ApoA-I(1^186) backbone £exibility
Relative £exibility along the backbone chain was estimated by com-
paring the signal intensities in the 3D HNCO spectrum. The line
intensity in this type of spectrum is a complex function of defocusing
and refocusing delays in the pulse sequence, the T2 values (or 1HN,
15N and 13CP line widths) and the spin^spin coupling constants 1JNH
and 1JNC0 . All of these parameters, except T2 values, are essentially the
same for each amino acid in a protein, so the di¡erence in line in-
tensities will be, to ¢rst approximation, a function of only the corre-
sponding T2 values. In other words, the 3D HNCO pulse sequence
works like a T2 ¢lter, and is the main reason it is impossible to get 3D
spectra for large proteins with short T2 values. In turn, the T2 values
are functions of magnetic interactions between nuclei (that are, again,
mainly the same for backbone HN, N and CP of each residue), and of
£exibility of the amino acid residue. Thus, the di¡erence in line in-
tensities in a 3D HNCO spectrum is mainly related to the di¡erence in
£exibility along the protein backbone chain, with greater line intensity
corresponding to greater £exibility.
3. Results
ApoA-I(1^186), which lacks the C-terminal fragment, resi-
dues 187^243 in the native protein, is secreted as a normally
folded protein. CD analyses of the lipid-free protein indicate a
45.5% K-helix content compared to 49% for native apoA-I.
Like wild-type apoA-I, it binds phospholipids in the presence
of cholate and can form discoidal lipoproteins with two apoA-
I per particle that elicit normal rates of di¡usional cellular
cholesterol e¥ux [15]. Deletion of residues 187^243 removes
a high a⁄nity lipid binding domain [33] and, as expected,
apoA-I(1^186) displays a reduced DMPC clearance and re-
duced ability to mobilize cellular lipids [15].
3.1. Strategy for assignment of apoA-I(1^186) NMR spectra
The backbone resonances were assigned from a combina-
tion of triple-resonance constant time experiments (HNCO,
HNCA, HN(CO)CA and HN(CA)CO), and intraresidual
and sequential NOEs (3D 15N-edited NOESY). Sequential
assignments of backbone HN, 15NH, 13CK and 13CP signals
were obtained from correlation of sequential and intraresidual
scalar connectivities observed in the series of 3D experiments.
Intraresidual CK(i)-N(i)-H(i) and sequential CK(i31)-N(i)-H(i)
scalar connectivities were taken from HNCA and HN(CO)CA
spectra, respectively. Some CK(i31)-N(i)-H(i) scalar connec-
tivities were observed in the HNCANH spectrum. Intraresid-
ual CP(i)-N(i)-H(i) and sequential CP(i31)-N(i)-H(i) scalar
connectivities were taken from HN(CA)CO and HNCO spec-
tra, respectively. The pattern of ‘walking strategy’ is illus-
trated by the superposition of HNCO and HN(CA)CO spec-
tra (Fig. 1). In some cases this kind of double scalar
correlation between adjacent amino acid residues was not
su⁄cient for unambiguous assignment and additional NOE
information concerning sequential dNN connectivities was
used from the 15N-edited NOESY-HSQC spectrum. The HK
chemical shifts were extracted from the HN(COCA)HA spec-
trum. The types of amino acids were determined from the
CBCA(CO)NH spectrum, when it was possible. Otherwise,
they were determined from 15N-edited NOESY-HSQC, to-
TALOS prediction CSI analog
Good prediction for K-helix conformation +1
No de¢nite prediction 0
Good prediction for L-(extended) conformation 31
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Fig. 2. 2D 1H-15N HSQC correlation spectrum of apoA-I(1^186). The cross signals, mainly representing one amino acid, are labeled with their
residue name and number. The signals from N1H of Trp side chains are in a rectangle at the left bottom corner. Folded in 15N dimension
peaks from Arg side chains are in the circle. NH2 signals from Asn and Gln side chains are connected by straight lines. Signals labeled with
NQ184, GQ185, GQ186 belong presumably to the deamidated form of apoA-I(1^186) with N184 replaced by D184, and signals labeled with
NQ184, GQ185 and GQ186 belong to deamidated form of apoA-I with D184 in the form of L-amino acid. Signals labeled with S-7 and G-8 be-
long to the amino-terminal tag.
Fig. 1. 2D 13CP strip plots taken from the 3D HN(CA)CO (gray) and 3D HNCO (black) spectra of apoA-I(1^186). By superimposing the strips
the sequential ‘walk’ is illustrated by the arrows.
FEBS 24466 4-1-01
M. Okon et al./FEBS Letters 487 (2001) 390^396392
gether with the unique combination of 15N, 13CK and 13CP
signal chemical shifts.
Because of speci¢c sequence Pro3-Pro4, i.e. with no HN
proton at Pro4, the signals from Pro3, as well as Glu110
and Pro121, were not found. The HN signals from the ¢rst
Met and Arg as well as from ¢ve His residues in the 11 residue
‘leader’ were not found probably due to fast exchange with
solvent, thus implying an absence of regular structure for this
region. Consistent with this ¢nding, it was shown that this
amino-terminal tag of six histidines added to native apoA-I
does not change the physicochemical properties of the protein
or its ability to interact with phospholipids and to promote
cholesterol esteri¢cation and cellular cholesterol e¥ux [14].
3.2. Characteristics of apoA-I(1^186) heteronuclear
2D NMR spectra in SDS solution
The 2D 1H/15N HSQC spectrum of apoA-I(1^186) is shown
in Fig. 2. A very small dispersion of HN chemical shifts, only
1.2 ppm, is apparent. This small dispersion, as well as broad
(20^30 Hz) proton line widths, lead to strong signal overlap in
the HSQC spectrum. Only 55^60 signals (about 30%), mainly
from Ala, Thr, Ser and Gly residues, are well resolved in the
HSQC spectrum. The strong overlapping signals made it dif-
¢cult to assign shifts from HSQC-based 3D spectra like NO-
ESY, and to obtain suitable relaxation measurements to de-
scribe intramolecular dynamics. Only 3D 1H/13C/15N
experiments give well resolved apoA-I(1^186) spectra. Anoth-
er feature of the apoA-I(1^186) 2D HSQC and 3D spectra ^
the wide range of signal intensities ^ will be described in
Section 3.4.
3.3. Secondary structure of apoA-I(1^186) in SDS solution
The secondary structure of apoA-I(1^186) is shown in Fig.
3. Residues 1^6 are ‘unordered’. That is, they are not truly
random coil because, while CSI does not predict any de¢nite
structure, the x, 8 plot (Fig. 3) shows phi and psi matches for
some contribution from L-(extended) structures accompanied
by strong RMS deviations (Fig. 4) in the TALOS prediction.
Residues 8^32 form a well-de¢ned helix. The helix appears
distorted at the Gly26 position, which may be the result of
a bend. Residues 33^44 are unordered. Residues 45^64 con-
stitute the next K-helix (the ¢rst predicted tandem helical re-
peat (3)). Some distortion of the helix may take place at the
Asn49 position. Residues 67^77 adopt an 11-mer K-helix (ex-
actly three turns of an ideal K-helix). However, the region 78^
82 appears to be unstructured, with the helix resuming for the
next ¢ve residues (83^87). Segment 88^98, predicted helical
repeat 3, is the ¢rst of two predicted 11-mer helices and CSI
and TALOS calculations con¢rm an K-helical region except
the ¢rst two (Lys88 and Asp89) and last one (Glu98) residues.
Starting at Pro99 the segment 99^120, helical repeat 4, is an
K-helical region (except Pro99). Segment 121^142, helical re-
peat 5, is a continuation of the previous K-helix except for
Lys141 and Ser142. Thus, there is probably an unbroken hel-
ical segment of 41 residues in this region (Fig. 3). Segment
143^164, helical repeat 6, consists of an K-helix from 146 to
162. Segment 165^186, helical repeat 7, consists of K-helix
from 166^181, according to TALOS, and we include Pro165
as a helix initiator. The rest of the protein (residues 182^186)
does not appear to have a de¢nite structure but this is no
doubt due to fraying of the C-terminus. It is interesting to
note that the domain of apoA-I involved in LCAT activation
is helix 6 (residues 144^165) [8,34,35], although adjacent heli-
ces, mostly helix 7, partially contribute to activation [35].
Comparison of HNCA, HN(CO)CA and CBCA(CO)NH
spectra of apoA-I(1^186) shows that Asn184 is mainly in
the form of L-amino acid (58%), which can be a consequence
of spontaneous deamidation to Asp184.
3.4. Overall £exibility of apoA-I(1^186) in lipid complexes
The salient feature of the NMR spectra of the protein is the
wide range of signal intensities along the sequence. The ratios
Imax/Imin from the 3D HNCO vary greater than 10-fold (Fig.
Fig. 3. Summary of structural information obtained from NMR
spectra. From bottom to top: consensus of HK, 13CK and CP CSI
values; phi (¢lled circles) and psi (open circles) angle values pre-
dicted by TALOS; apoA-I(1^186) solution secondary structure (K-
helices are depicted by rectangles and irregular regions by lines).
The average backbone torsion angles among all well-de¢ned K-heli-
ces (RMSD9 8 degrees) are: xaver =363.2 þ 1.8 and 8aver =
342.2 þ 1.7 degrees.
Fig. 4. Flexibility of apoA-I(1^186) in solution. From bottom to
top: Line intensities in 3D HNCO spectrum; 13CK secondary chemi-
cal shifts; RMS deviations of phi (¢lled circles) and psi (open
circles) values obtained by TALOS; apoA-I(1^186) solution second-
ary structure.
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4, bottom), which undoubtedly is a consequence of di¡erent
£exibility along the polypeptide chain (see Section 2). Another
parameter that may be used to provide a qualitative picture of
protein £exibility, is secondary chemical shifts. Flexible back-
bone regions exhibit secondary chemical shifts closer to ran-
dom coil values [28].
It can be seen that the line intensities (Fig. 4, bottom) decay
almost monotonically from the ends to the middle of the
protein, except for the maxima in the region 32^44. This cor-
responds to decreasing backbone chain £exibility as the mid-
dle of the protein is approached from either end. For the
region 32^44, the greater HNCO intensities and decreased
13CK secondary shifts (Fig. 4, middle) complement each other
very well. The calculated RMS deviations from TALOS pre-
dicted phi and psi angles are also increased dramatically in
this region (Fig. 4, top). One immediately apparent conclusion
from this comparison is that there is a very £exible region
from residue 32 to 44. Flexibility of this region seems to be
comparable with the £exibility of the last six C-terminal res-
idues and it allows the helical structural domain at the N-
terminus (8^32) to act independently from the majority of
the apoA-I(1^186) structural element. The other helices (hel-
ical repeats 1^7) form parts of a long, continuous helical
structure interrupted by 2^5 residue irregular regions, whose
individual £exibility is comparable with the overall £exibility
of the main chain (Fig. 4, bottom). Furthermore, the reduced
secondary chemical shift values and increased RMS deviations
of predicted phi and psi angles, which are typical for these
regions (Fig. 4, middle and top), lead us to propose a rela-
tively slow intrinsic mobility in the irregular interhelical re-
gions, allowing the helical repeats to change their reciprocal
orientation. This mobility would allow the protein to opti-
mally adopt a di¡erent conformation as conditions warrant.
4. Discussion
4.1. Comparison of CSI and TALOS predictions
There were almost no discrepancies between CSI and TA-
LOS predictions along the polypeptide chain with the excep-
tion of proline residues at the beginning of K-helices, which
were assigned by TALOS to K-helix con¢guration, whereas
strong CSI criteria (13CP, 13CK secondary shift s 4 ppm
[30]) excluded the proline residues from an K-helix con¢gura-
tion. Some other disagreements were found at the ends of K-
helices. For example, the end of helix G* (residues 33, 34) and
the beginning of helical repeat 1 (residues 43, 44) were as-
signed by CSI to K-helix, whereas TALOS did not give any
de¢nite predictions for these residues.
4.2. Comparison with other apoA-I structures
We compared the region 142^187 in apoA-I(1^186) with the
high resolution solution structure of the synthetic peptide,
apoA-I(142^187) [13], under identical conditions (aqueous so-
lution in the presence of SDS). The structures are almost
identical and consist of two K-helices: 146^162 and 168^182
in the synthetic peptide and 146^162 and 166^181 in apoA-
I(1^186).
The NMR-derived secondary structure of apoA-I(1^186) in
lipid-mimetic solution resembles the monomer unit of the A/B
dimer in the four helix bundle determined by Borhani et al.
[36] from X-ray data of lipid-free tetramers of apoA-I(44^
243). The exceptions are 2^5 residue irregular segments be-
tween helical repeats and an irregular unpredicted segment,
residues 78^82, in helical repeat 2. However, our data do
not support the presence of dimers or tetramers of apoA-I
in an SDS complex. SDS^polyacrylamide gel electrophoresis
of the [u-13C; u-15N; u-50% 2H]apoA-I(1^186) showed that it
is a monomer in SDS. In addition, we did not see any NMR
indications of the presence of dimers or tetramers in solution
like double or extremely broadened sets of peaks.
The absence of any oligomeric structure in a lipid environ-
ment may be due to the addition of residues 1^43, which,
when deleted, results in an increased apoA-I oligomerization
[36,37].
4.3. Irregular segments of apoA-I(1^186) between helical
repeats
A characteristic of apoA-I is its lability, i.e. its ability to
change conformation in order to bind to small (HDL) or large
(VLDL) lipoprotein complexes, and to activate LCAT. This is
not apparent from the rigid X-ray structure of lipid-free
apoA-I(44^243) [36]. The X-ray structure consists of four mol-
ecules in the asymmetric unit, each molecule structure consist-
ing ‘almost entirely of a pseudocontinuous, amphipathic K-
helix’ [36], although the X-ray structure is not an ideal K-
helix. The authors note ‘bends’ and ‘kinks’ at proline posi-
tions. Mean kink angle and its standard deviation are larger
than that found in other structures and ‘regions of monomer
involved in crystal packing contacts are better ordered than
those that are not’ [36]. They also describe one mostly mobile,
extended, non-helical region at the beginning of helical repeat
10 (residues 220^227).
It is quite possible that ‘bends’ and ‘kinks’ between helices
found in crystal apoA-I(44^243) structure (which is addition-
ally stabilized by ‘monomer^monomer’ and ‘dimer^dimer’ in-
teractions) become less rigid and/or more disordered in solu-
tion (and in the complex with lipid). This should lead to an
increasing number of possible local and global conformations.
Our solution apoA-I(1^186) structure consisting of a number
of rigid helices connected by £exible links can explain the
labile properties of apoA-I.
Another result of the present apoA-I(1^186) NMR struc-
ture, which is not present in X-ray [36] or predicted [3] apoA-I
structures, is an irregular segment, 78^82, in the helical repeat
2 (residues 66^87). It is interesting to note that Glu78 at the
beginning of this segment is at the 13th position of the 22
residue helical repeat 2. It was found [38] that the presence
of glutamic acid at the 13th position in peptide analogues of
apoA-I leads to reduced lipid a⁄nity together with an in-
creased LCAT activating ability of the peptide. It was also
shown that inclusion of a proline within the sequence of pu-
tative helix also decreases the lipid a⁄nity of the peptide [39].
The reduced lipid a⁄nity of the amphipathic segment may
distort or destroy its helical structure, because interaction
with lipid has a profound e¡ect on the conformation of pro-
tein that interacts with it [3]. Consequently, our ¢ndings, sum-
marized in Figs. 3 and 4, of irregular segments of 2^5 residues
may result from speci¢c protein^lipid interaction.
4.4. N-terminal domain
This is the ¢rst report of the structure of the N-terminal
segment of apoA-I, residues 1^43, as a part of apoA-I(1^186).
It was predicted that this region contains an amphipathic
(class G*) helix comprising residues 8^33 whereas regions 1^
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7 and 34^43 are disordered [3]. The amino-terminus (residues
1^33) of apoA-I is highly conserved among di¡erent apolipo-
protein species and was initially thought to be a functional
domain of apoA-I [40]. The estimations of lipid a⁄nity of this
domain, using model peptides, were not straightforward,
changing from ‘weak, if at all’ [3] to ‘moderate’ [41]. The
structure of the corresponding peptide, consisting of this do-
main, was random in bu¡er and adopted a helical conforma-
tion (52% helicity) in the presence of lipid micelles [41]. Tak-
ing into account that deletion of segment 1^43 ‘has no
measurable e¡ect on apoA-I lipid association’ [42], this do-
main was arbitrarily assigned a compact globular structure in
a molecular belt model for apoA-I in discoidal HDL [43].
Deletion of the domain was shown to induce oligomer for-
mation of apoA-I [36,37], thus it may therefore be involved in
the stabilization of apoA-I in its lipid-free or -poor form like
in pre-L1-HDL, and its deletion changes the conformation of
lipid-free apoA-I to that of lipid-bound [42].
Our data show that the N-terminal segment of apoA-I(1^
186), residues 1^44, contains an K-helical region 8^32 in the
complex with SDS whereas regions 1^7 and 33^44 are disor-
dered. That is in a good agreement with prediction [3] and
gives a mean value of 76% helicity for domain 1^33. The two
features of the N-terminal domain, its moderate lipid a⁄nity
[41], which is con¢rmed by the fact that we observe the for-
mation of an amphipathic helical region from residues 8^32 in
the presence of SDS, and the separation of this helix from the
next one by an unordered linker from residue 33 to residue 44
(Figs. 3 and 4), prompt us to suggest a primary anchor role
for this domain. That is, the N-terminal helix’s lipid binding
properties and independence would easily allow it to lift o¡
the lipoprotein surface for binding to cell surfaces or recep-
tors. Burgess et al. [15] had previously suggested that apoA-I
binds to a second binding site on the cell surface by the N-
terminal domain (residues 1^100). This domain was also
shown to interact with the central domain of apoA-I, espe-
cially in small LpA-I particles [44^46], and was proposed to
regulate LCAT activation [37]. The ability of the N-terminal
domain to behave independently from the rest of the molecule
may therefore be important for apoA-I structure and func-
tion.
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